Huapont Taps US Partner To Ride China Precision Medicine Wave
2016 is the year for precision medicine therapies to be included in China’s National Major Project for Innovation. Looking to seize market opportunity in the newly funded area, Huapont Life Sciences has linked up with and invested in a US bioventure partner for a gene therapy for refractory angina.
You may also be interested in...
Chinese biotech Innovative Cellular Therapeutics has reported promising results for its CAR-T cell immunotherapy in a small leukemia study, and the company is now planning to expand its clinical program into new indications including solid tumors, and to explore global markets.
Amid China’s big push into precision medicine, the Chinese bioventure CARsgen is developing what it says is the world’s first CAR-T cell immunotherapy for liver cancer and is seeking a global partner to develop its proprietary therapies. The company is also aiming to raise additional funding to advance its pipeline.
Metastatic tumors, diabetes, cardiovascular and rare diseases are among the areas being targeted in China’s new precision medicine initiative, in a bet that could be worth $10 billion by 2030.